AUSTRALIA Trends and Developments Contributed by: Suzy Madar, Matthew Swinn, Kate Hay and Scott Bouvier, Mallesons
Mallesons Level 61 Governor Phillip Tower One Farrer Place Sydney NSW 2000 Australia
Tel: +61 2 9296 2000 Fax: +61 2 9296 3999 Email: syd@mallesons.com Web: www.mallesons.com/au/en/home.html
Introduction: From Approval to Accountability Australia enters 2026 at a turning point for the life sciences sector. Technology adoption, new market entrants and hybrid models of care are no longer emerging trends but operating realities, embedded in service delivery, financing and system governance. This comes alongside tighter regulatory expectations, more active enforcement of consumer protections, and increasingly targeted public spending. The centre of gravity has shifted from tentative approval to embedded accountability. The question is no longer whether digital, AI-enabled and advanced therapies should be deployed, but how their perfor- mance will be evidenced in real-world settings, how residual risk is allocated across manufacturers, plat- forms and providers, and how quickly regulators will intervene when claims, data or controls fall short. Demand and delivery are being shaped by aging demographics, the burden and public cost of chronic disease, and growing expectations around mental health and preventative medicine, with products being used over longer horizons and services increasingly being delivered in home and community settings. As care moves beyond traditional clinical environments, safety concerns that once sat at the margins – such as cybersecurity, interoperability, complaints-handling and continuity – become central system design issues. These shifts also sharpen longstanding equity ques- tions, including for First Nations communities, where data sovereignty, culturally safe consent and commu-
nity governance are critical controls. As care becomes more distributed, data-intensive and long-lived, accountability increasingly turns on whether underly- ing systems are capable of sustaining safety, equity and performance over time, rather than on isolated clinical or product-level decisions. Telehealth and virtual care are pillars that underlie these changes. Hybrid models blur the boundaries between clinical practice, digital platforms and con- sumer services, exposing gaps in responsibility where regulatory frameworks, indemnity arrangements and privacy obligations do not align. The regulatory task is no longer to accommodate these models but to ensure that responsibility for patient safety, data protection and continuity of care is clearly allocated across settings, providers and technologies, particu- larly where harm may emerge incrementally rather than at a single point of failure. Against this backdrop, Australia’s therapeutic goods regulator is recalibrating its approach. The Thera- peutic Goods Administration (TGA) has shifted deci- sively from a primary focus on market entry to active oversight across the full product life cycle, reflecting both the maturing of advanced therapeutics and digi- tal health technologies and heightened sensitivity to patient safety, data integrity and public confidence. Regulatory risk is increasingly shaped by how prod- ucts and technologies are governed after they have been deployed, including how claims are substanti- ated, how changes are managed over time, and how emerging risks are detected and addressed.
25 CHAMBERS.COM
Powered by FlippingBook